Yana G. Najjar
机构: UPMC Hillman Cancer Center
每年引用次数
引用次数
引用: 2,564
H-指数: 17
I10-指数 : 21
出版物: 84
Abstract CT183: Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)
Benjamin Izar , Dmitriy Zamarin , David R Spigel , Christopher J Hoimes
Cancer Research 84 ( 7_Supplement) CT183 -CT183
2024
Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes
Lilit Karapetyan , Hassan M AbuShukair , Aofei Li , Andrew Knight
Frontiers in Immunology 14 1171978 -1171978
3
2023
Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum: Outcomes for patients with melanoma.
Lilit Karapetyan , Hassan Mohammed Abushukair , Aofei Li , Andrew David Knight
Journal of Clinical Oncology 41 ( 16_suppl) 9565 -9565
2023
Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma
Ryan C Augustin , Sarah Newman , Aofei Li , Marion Joy
Journal for ImmunoTherapy of Cancer 11 ( 10)
6
2023
Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel).
Lilit Karapetyan , Arivarasan Karunamurthy , Anthony Cillo , Shuachao Wang
Journal of Clinical Oncology 42 ( 16_suppl) 9525 -9525
2024
Randomized phase II trial of pembrolizumab/lenvatinib (P+ L)+/-responder fecal microbiota transplant (R-FMT) in PD-1 relapsed/refractory (R/R) cutaneous melanoma (MEL).
Diwakar Davar , Hong Wang , Drew Hurd , Madison Nguyen
Journal of Clinical Oncology 42 ( 16_suppl) TPS9607 -TPS9607
2024
Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy
Chad Pickering , Paul Aiyetan , Gege Xu , Alan Mitchell
Frontiers in Immunology 14 1187332 -1187332
5
2023
43 Harnessing the power of glycoproteomics: a cutting-edge approach for predicting treatment efficacy in metastatic melanoma with immune checkpoint inhibitors
Yana G Najjar , Chad Pickering , Paul Aiyetan , Gege Xu
Journal for ImmunoTherapy of Cancer 11 ( Suppl 1)
1
2023
Immune-related adverse events in PD-1 treated melanoma and impact upon anti-tumor efficacy: a real world analysis
Melissa L Bastacky , Hong Wang , Dylan Fortman , Zahra Rahman
Frontiers in Oncology 11 749064 -749064
26
2021
A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma
Saba S Shaikh , Xi Yang , Dylan D Fortman , Hong Wang
Journal of the American Academy of Dermatology 87 ( 4) 906 -908
7
2022
Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.
Lilit Karapetyan , Arivarasan Karunamurthy , Anthony Cillo , Anjali Rohatgi
Journal of Clinical Oncology 40 ( 16_suppl) 9514 -9514
2
2022
Impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma.
Saba Shaikh , Xi Yang , Dylan Fortman , Hong Wang
Journal of Clinical Oncology 39 ( 15_suppl) e21579 -e21579
2
2021
A phase 1/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis.
Jabra Zarka , Urvashi Mitbander Joshi , Amy Rose , Yan Zang
Journal of Clinical Oncology 42 ( 16_suppl) TPS9614 -TPS9614
2024
Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC).
Florent Amatore , Shaum Sridharan , Arivarasan Karunamurthy , Hong Wang
Journal of Clinical Oncology 42 ( 16_suppl) 9591 -9591
2024
A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma.
Urvashi Mitbander Joshi , Saba Shaikh , Yan Zang , Hong Wang
Journal of Clinical Oncology 42 ( 16_suppl) TPS9600 -TPS9600
2024
Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy
William H Hicks , Lauren C Gattie , Jeffrey I Traylor , Diwakar Davar
bioRxiv
2024
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Lisa H Butterfield , Yana G Najjar
Nature Reviews Immunology 1 -18
19
2023
Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study
Ryan C Augustin , Ziyu Huang , Fei Ding , Shuyan Zhai
Frontiers in Oncology 13 1075823 -1075823
7
2023
Combined Pd-1 and Ctla-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma
Erin Elizabeth McGillivray , Karam Ashouri , Eftychia Chatziioannou , Jesús Antonio Ocejo Gallegos
764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors
Manojkumar Bupathi , Judy S Wang , Siwen Hu-Lieskovan , Sarina A Piha-Paul
Journal for ImmunoTherapy of Cancer 11 ( Suppl 1)
1
2023